Dynavax Announces Presentation of Clinical Data at ASH Annual Meeting
(firmenpresse) - BERKELEY, CA -- (Marketwired) -- 11/30/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present clinical data at the 57th American Society of Hematology (ASH) Annual Meeting this weekend in Orlando, Florida. The details for the poster presentation are as follows:
: Saturday, December 5, 2015, 5:30pm - 7:30pm EST
: Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN.
: 616
: Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster I
: 1539
: Hall A, Level 2 (Orange County Convention Center)
Please click for the full abstract. The poster presentation with updated data will be made available on or after December 5, 2015.
SD-101, the subject of ASH abstract 1539, is Dynavax''s proprietary, second-generation, TLR 9 agonist CpG-C class oligodeoxynucleotide. SD-101 activates multiple anti-tumor activities of innate immune cells and activates plasmacytoid dendritic cells to stimulate T cells specific for antigens released from dying tumor cells. TLR9 agonists such as SD-101 enhance T and B cell responses and provide potent Type 1 interferon induction and maturation of plasmacytoid dendritic cells to antigen-presenting cells. SD-101 is being evaluated in several Phase 1/2 oncology studies to assess its preliminary safety and activity.
Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax''s lead product candidates are HEPLISAV-B™, a Phase 3 investigational adult hepatitis B vaccine and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information, visit .
Michael Ostrach
Chief Financial Officer
510-665-7257
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 30.11.2015 - 15:00 Uhr
Sprache: Deutsch
News-ID 1401301
Anzahl Zeichen: 2772
contact information:
Contact person:
Town:
BERKELEY, CA
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 257 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Dynavax Announces Presentation of Clinical Data at ASH Annual Meeting
"
steht unter der journalistisch-redaktionellen Verantwortung von
Dynavax Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
